U.S., May 21 -- ClinicalTrials.gov registry received information related to the study (NCT06981078) titled 'A Phase 2b Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD' on May 09.
Brief Summary: The purpose of this study is to assess the efficacy and safety of verekitug (UPB-101) in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), an inflammatory lung disease.
Study Start Date: Aug., 2025
Study Type: INTERVENTIONAL
Condition:
Chronic Obstructive Pulmonary Disease
Intervention:
DRUG: Verekitug
Verekitug (UPB-101) formulated solution
OTHER: Placebo
Matching Placebo to Verekitug (UPB-101)
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Upstream Bio Inc.
Published by H...